Mantle cell lymphoma future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
* In addition to the ongoing assessment of new monoclonal antibody-based therapies, the continued development of targeted molecular signaling inhibitors based on the underlying biology of MCL is an approach that will potentially yield fruitful results in this disease. | * In addition to the ongoing assessment of new monoclonal antibody-based therapies, the continued development of targeted molecular signaling inhibitors based on the underlying biology of MCL is an approach that will potentially yield fruitful results in this disease. | ||
* Some of the current therapies under clinical investigation are as follows: | * Some of the current therapies under clinical investigation are as follows: | ||
** | ** Chimeric antigen receptor T-cell (CAR-T) therapy is being used in a phase II study of CAR-T therapy in relapsed MCL. | ||
*** | |||
==References== | ==References== | ||
Revision as of 19:40, 12 December 2018
|
Mantle cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mantle cell lymphoma future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Mantle cell lymphoma future or investigational therapies |
|
FDA on Mantle cell lymphoma future or investigational therapies |
|
Mantle cell lymphoma future or investigational therapies in the news |
|
Blogs on Mantle cell lymphoma future or investigational therapies |
|
Risk calculators and risk factors for Mantle cell lymphoma future or investigational therapies |
Investigational therapies
- Recent advances in the understanding of the pathogenesis of mantle cell lymphoma has led to the development of targeted therapies which have shown potential promise as effective therapeutic approaches in the future..
- In addition to the ongoing assessment of new monoclonal antibody-based therapies, the continued development of targeted molecular signaling inhibitors based on the underlying biology of MCL is an approach that will potentially yield fruitful results in this disease.
- Some of the current therapies under clinical investigation are as follows:
- Chimeric antigen receptor T-cell (CAR-T) therapy is being used in a phase II study of CAR-T therapy in relapsed MCL.
- Chimeric antigen receptor T-cell (CAR-T) therapy is being used in a phase II study of CAR-T therapy in relapsed MCL.